Ampio Pharmaceuticals IncFind Ratings Reports
AMPIO PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Sales have remained unchanged, but net income increased. AMPIO PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 3.36 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 70.26% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY16||Q1 FY15|
|Net Sales ($mil)||0.0||0.0|
|Net Income ($mil)||-6.77||-7.28|
|Balance Sheet||Q1 FY16||Q1 FY15|
|Cash & Equiv. ($mil)||11.11||43.27|
|Total Assets ($mil)||21.85||62.62|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q1 FY16||Q1 FY15|
|Gross Profit Margin||0.0||0.0|
|Return on Assets||-144.09||-56.15|
|Return on Equity||-175.71||-55.28|
|Debt||Q1 FY16||Q1 FY15|
|Share Data||Q1 FY16||Q1 FY15|
|Shares outstanding (mil)||52.02||51.99|
|Div / share||0.0||0.0|
|Book value / share||0.34||1.16|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||858339.0||181526.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 2.87 indicates valuation on par with the S&P 500 average of 2.81 and a significant discount versus the industry average of 8.86. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, AMPIO PHARMACEUTICALS INC seems to be trading at a premium to investment alternatives within the industry.
|AMPE NM||Peers 45.39||AMPE NM||Peers 31.23|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
AMPE's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AMPE's P/CF is negative making the measure meaningless.
|AMPE NA||Peers 16.56||AMPE NA||Peers 0.58|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|AMPE 2.87||Peers 8.86||AMPE 7.70||Peers -19.27|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AMPE is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
AMPE is expected to have an earnings growth rate that significantly exceeds its peers.
|AMPE 45.17||Peers 23.05||AMPE 1684.37||Peers 6.33|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AMPE is trading at a significant premium to its industry.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
AMPE has a sales growth rate that significantly exceeds its peers.